Full text is available at the source.
Multistage oral astaxanthin targeted delivery system: Increasing serotonin levels with a dual therapeutic effect for alleviating inflammatory bowel disease and psychiatric disorders
Oral astaxanthin delivery system that raises serotonin to help both inflammatory bowel disease and mental health conditions
AI simplified
Abstract
ALM@AG significantly reduced inflammation and improved gut health in a model of colitis.
- Astaxanthin (AXT) is an antioxidant that may help treat inflammatory bowel disease (IBD) and associated psychiatric disorders.
- ALM@AG enhances the bioavailability and targeted delivery of AXT to colon lesions.
- The system demonstrated effectiveness in reducing inflammation and modulating gut microbiota.
- ALM@AG helped repair the intestinal barrier and restore metabolic balance.
- Treatment with ALM@AG alleviated depression-like behaviors linked to colitis by regulating neurotransmitters and reducing brain inflammation.
- Interactions among genes, microbiota, and metabolites were explored in the context of IBD and psychiatric disorders.
AI simplified